Bioqube Ventures
Bioqube Ventures is a Belgium-based life sciences venture capital firm managing Bioqube Factory Funds I and II to back early-stage European biotechs developing first- or best-in-class therapeutics, serving both portfolio companies and institutional/strategic limited partners.
- Company typePrivate
- Founded2015
- HeadquartersHasselt, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Bioqube Ventures does
Bioqube Ventures is a Belgium-based life sciences venture capital firm founded in 2015 by Debora Dumont and Nico Vandervelpen. The firm invests in European biotechnology companies developing first- or best-in-class therapeutics to address major unmet medical needs, supporting companies from inception through early clinical milestones with a stage-agnostic, transatlantic model spanning Belgium (Brussels and Hasselt) and San Diego.
The firm's core products are its venture capital funds — Bioqube Factory Fund I (first closing €60 million in June 2020, targeting up to €100 million) and Bioqube Factory Fund II (supported by the European Union under the InvestEU Fund). Investment decisions are guided by a proprietary IIMPACT framework covering Innovation, Impact, Management of ESG, Patient population, Action on health economics, Curative potential, and Treatments for unmet need, with the firm operating as an SFDR Article 8 fund. Bioqube originated from an incubation model on the Janssen Pharmaceutica R&D campus in Belgium, and its portfolio includes over 20 companies such as Bicara Therapeutics, SynOx Therapeutics, Spica Therapeutics, Actithera, Anavo Therapeutics, Commit Biologics, and CatalYm.
Bioqube generates revenue through two primary streams: (1) management fees on its venture capital funds, with capital sourced from institutional LPs (European Investment Fund via InnovFin Equity, PMV, FPIM, Belfius Insurance) and strategic investors (Genmab, Johnson & Johnson Innovation JJDC), and (2) investment returns through equity stakes in portfolio companies, with exits via IPOs or acquisitions. Value-added differentiation comes from operational partnerships with Lonza (preferential biologics/small molecule manufacturing) and IQVIA (clinical and commercial guidance).
Bioqube Ventures firmographics
Firmographics- Name
- Bioqube Ventures
- Legal name
- Bioqube Ventures NV
- Website
- https://bioqubeventures.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bioqube Ventures is a Belgium-based life sciences venture capital firm managing Bioqube Factory Funds I and II to back early-stage European biotechs developing first- or best-in-class therapeutics, serving both portfolio companies and institutional/strategic limited partners.
- Ownership category
- akta.pro rank
Where Bioqube Ventures is headquartered
LocationHeadquarters
- HQ city
- Hasselt
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
Bioqube Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Investment Returns: Bioqube Ventures generates returns through equity investments in portfolio companies, expecting exits through IPOs or acquisitions. The firm has a track record of high-value exits from its portfolio companies.
- Fund Management Fees: Managing venture capital funds including Bioqube Factory Fund I and Fund II, with management fees from institutional and private investors including EIF, PMV, FPIM, Belfius Insurance, and strategic investors like Genmab and Johnson & Johnson Innovation JJDC.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Bioqube Ventures product offering
Product offeringCore offering
Bioqube Ventures is a specialist life sciences venture capital firm that manages venture capital funds (Bioqube Factory Fund I and Fund II) investing equity capital into early-stage European and US biotechnology companies developing first- or best-in-class therapeutics to address major unmet medical needs. The firm provides portfolio companies with hands-on support across science, development, and strategy, from inception through early clinical milestones, using a proprietary IIMPACT investment evaluation framework.
Product overview
Bioqube Ventures operates as a life sciences venture capital firm offering investment funds rather than traditional products. The firm manages two venture capital funds - Bioqube Factory Fund I (targeting up to 100M EUR with investments in European therapeutics) and Bioqube Factory Fund II (supported by InvestEU). Through these funds, the company provides capital, expertise, and operational support to early-stage biotech companies developing first- or best-in-class therapeutics. The investment approach combines venture creation, early-stage company building, and selective clinical co-investment, with a transatlantic model spanning Europe and the United States.
Differentiator
Problem solved
Functional benefit
Brands
- Bioqube Factory Fund I: Early-stage venture capital fund focused on development of therapeutic assets and technology platforms in Europe
- Bioqube Factory Fund II
Products and services
- Bioqube Factory Fund I Early-stage venture capital fund focused on development of therapeutic assets and technology platforms in Europe, targeting up to €100 million, with a dual investment strategy including traditional investments and 'Create' projects requiring early-stage de-risking. Available to institutional and strategic limited partners and deployed into first- or best-in-class therapeutics companies across Benelux, France, Germany and beyond.
- Bioqube Factory Fund II Second-generation venture capital fund following the success of Bioqube Factory Fund I, supported by the European Union under the InvestEU Fund, continuing the firm's strategy of investing in early-stage European biotech therapeutics companies developing first- or best-in-class medicines.
Quantifiable outcome
- Multiple high-value exits achieved from portfolio companies
- +2 more outcomes
Companies that use Bioqube Ventures
Customer profileSegments2 records
Ideal customer profiles2 records
Bioqube Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bioqube Ventures partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and strategic.
- LonzacoreLonza and Bioqube Ventures signed a Framework Agreement for the future development and manufacture of biologics and small molecules for Bioqube's portfolio companies, providing preferential access to manufacturing capabilities.
- IQVIAstrategicIQVIA is mentioned as a strategic partner providing complementary skills and industry guidance to Bioqube's portfolio companies.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Bioqube Ventures competitors and assessment
Company assessmentDirect peers
- Novo Seeds: Early-stage biotech investment arm of Novo Holdings, investing seed-to-Series A in Nordic and European therapeutic companies; comparable by stage focus (inception through early clinical) and European thesis.
- Forbion: Dutch-headquartered European biotech VC with a multi-fund platform investing from seed through late stage across therapeutics and growth; comparable in therapeutic focus and European footprint, though materially larger in AUM.
- Sofinnova Partners: Paris-based European biotech specialist VC managing multiple flagship and growth funds; one of the most established European life sciences investors and the most direct comparable to Bioqube by mandate and geography.
- LSP (Life Sciences Partners): Amsterdam-based European healthcare VC investing in therapeutics and medical devices across multiple funds; comparable European specialist peer though typically at later stages than Bioqube.
- BB Pureos Bioventures: Swiss-based biotech VC investing in private early-to-mid-stage therapeutic companies, backed by institutional and strategic LPs; comparable by stage, therapeutic focus and European mandate.
- Andera Partners (Life Sciences): French-based VC with dedicated Life Sciences franchise investing across Europe in therapeutics, medtech and diagnostics; directly comparable European biotech specialist with similar fund-size profile.
- Novartis Venture Fund / BioVentures (NVF): Strategic corporate venture arm of Novartis investing in early-stage therapeutic platforms globally; comparable to Bioqube's strategic-LP-backed model and focus on first/best-in-class therapeutics.
Regional players
- Capricorn Partners: Belgian-based VC manager with a dedicated HEALTH fund investing in therapeutics and diagnostics; directly comparable regional peer by domicile and early-stage therapeutic focus.
Broad incumbents
- GIMV: Listed Belgian investment company with a long-standing Life Sciences platform alongside its broader tech and sustainable businesses; comparable by Belgian HQ and life-sciences exposure, though broader in scope.
- Omega Funds: Boston- and London-based healthcare specialist investor spanning venture and crossover/growth; comparable by therapeutic focus, though with a much larger capital base and later-stage emphasis.
Market position
Strengths5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioqube Ventures social profiles
Digital presenceBioqube Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioqube Ventures leadership team
Management profileNumber of profiles
Profiles15 records
Bioqube Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioqube Ventures M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioqube Ventures
What does Bioqube Ventures do?
Bioqube Ventures is a specialist life sciences venture capital firm that manages venture capital funds (Bioqube Factory Fund I and Fund II) investing equity capital into early-stage European and US biotechnology companies developing first- or best-in-class therapeutics to address major unmet medical needs. The firm provides portfolio companies with hands-on support across science, development, and strategy, from inception through early clinical milestones, using a proprietary IIMPACT investment evaluation framework.
Is Bioqube Ventures a public or private company?
Bioqube Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bioqube Ventures founded?
Bioqube Ventures was founded in 2015. It employs 1 to 10 people.
Where is Bioqube Ventures based?
Bioqube Ventures is headquartered in Hasselt, Belgium, in the Europe region.
How does Bioqube Ventures make money?
Two revenue lines are on record. Investment Returns are the primary driver. The others are fund Management Fees.
Who are Bioqube Ventures's main competitors?
Direct peers on record are Novo Seeds, Forbion, Sofinnova Partners, LSP (Life Sciences Partners), BB Pureos Bioventures, Andera Partners (Life Sciences) and Novartis Venture Fund / BioVentures (NVF). Capricorn Partners is listed as a regional player. Broad incumbents are GIMV and Omega Funds.
Does Bioqube Ventures have an API?
No public API is recorded for Bioqube Ventures.